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Prevention and treatment of graft-versus-host disease (GVHD) remains a major challenge, given that current
T-cell depletion and mainstay immunosuppressive therapies compromise preexisting T-cell immunity, often
leading to severe infections and disease relapse. Thus, there is a critical need for novel anti-GVHD agents that
can spare protective T-cell memory. Here we show that milatuzumab (hLL1), a humanized anti-CD74
antagonist monoclonal antibody, can moderately reduce the numbers of CD74-expressing B cells and
myeloid dendritic cells, but has no effect on the survival of T cells that are CD74. Consequently, milatuzumab
inhibits allogeneic T-cell proliferation in mixed leukocyte reactions. In a human/mouse xenogeneic SCID
mouse model in which GVHD is induced and mediated by engrafted human CD4þ T cells and dendritic cells,
milatuzumab effectively prevents the onset and manifestations of acute GVHD, suppresses serum levels of
human IFN-g and IL-5, eliminates the inﬁltration of human lymphocytes into GVHD target organs (ie, lung,
liver, and spleen), and signiﬁcantly promotes survival (90% versus 20% for controls; P ¼ .0012). Importantly,
exposure to milatuzumab does not affect the number of cytomegalovirus-speciﬁc, IFN-geproducing human
CD8þ T cells in allogeneic mixed leukocyte reactions. These encouraging results warrant further exploration of
milatuzumab as a possible new therapeutic agent for GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION antigen-presenting cells (APCs), which include B cells,
Graft-versus-host disease (GVHD) is the major cause of
mortality and morbidity in patients undergoing allogeneic
hematopoietic stem cell transplantation (allo-HSCT),
a powerful and currently the sole curative therapy for many
malignant and nonmalignant hematologic diseases [1].
Prevention and treatment of GVHD remains a major chal-
lenge [2], given that contemporary T-cell depletion
and immunosuppressive therapies, although effective in
controlling GVHD in certain patients, compromise preexist-
ing T-cell immunity, leading to severe infections and disease
relapse [3-6]. Thus, there is a critical need for novel anti-
GVHD agents that spare protective T-cell memory.
Milatuzumab (hLL1) is a humanized IgG1k mAb that
reacts with human CD74 [7-9], the HLA class IIeassociated
invariant chain [10]. Previous studies found that milatuzu-
mab has potent cytotoxicity against CD74-expressing malig-
nant B cells in vitro and in xenograft models [7,11], which has
led to the ongoing clinical evaluation of milatuzumab in
relapsed or refractory B-cell malignancies [12]. More recent
preclinical studies [13] have demonstrated that milatuzumab
is capable of modulating human B cell proliferation, migra-
tion, and adhesion molecule expression, suggesting the
therapeutic potential of this mAb in autoimmune diseases.
As an HLA class II invariant chainmolecule, CD74 is widely
expressed in both hematopoietic and nonhematopoieticedgments on page 38.
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12.09.015monocytes, macrophages, Langerhans cells, dendritic cells
(DCs), and endothelial and certain epithelial cells [7,14].
Because both recipient and donor APCs, including non-
hematopoietic APCs, play critical roles in the initiation of
GVHD [15-24], we reasoned that milatuzumab might have
therapeutic potential for GVHD by affecting recipient and/or
donor APCs. The anti-GVHD potential of anti-CD74 mAb is
also supported by evidence that macrophage migration
inhibitory factor (MIF), the ligand of CD74 [25], is involved in
the development of acute GVHD in a murine model of allo-
geneic stem cell transplantation [26].
In this study, we demonstrate that milatuzumab selec-
tively reduces myeloid DCs (mDCs) and B cells, but not
plasmacytoid DCs (pDCs), monocytes, or T cells, in human
peripheral blood mononuclear cells (PBMCs). As a result,
milatuzumab inhibits allogeneic mixed lymphocyte reac-
tions (allo-MLRs); and in a human PBMC-transplanted SCID
mouse model (hu-PBL-SCID) [27], milatuzumab effectively
prevents acute GVHD, suppresses human cytokine storm,
eliminates inﬁltration of human lymphocytes in GVHD target
organs, and signiﬁcantly improves survival. Unlike alemtu-
zumab, an anti-CD52 mAb currently used clinically for GVHD
prevention, milatuzumab does not affect cytomegalovirus
(CMV)-speciﬁc T-cell immunity in vitro, suggesting that it
might be exploited as a novel agent for GVHD without
compromising preexisting antiviral immunity.MATERIALS AND METHODS
Antibodies and Reagents
Milatuzumab (hLL1), labetuzumab (hMN-14; a humanized anti-
CEACAM5 mAb) [28], epratuzumab (hLL2; a humanized anti-CD22 mAb)
[29], IMMU-T3 (a humanized anti-CD3 mAb), and hLL1-Fab-A3B3 (a fusion
protein of milatuzumab Fab fragment with CEACAM5 [CD66e] A3B3 domainTransplantation.
Figure 1. Milatuzumab selectively reduces myeloid DCs in human PBMCs. Human PBMCs were incubated with 5 mg/mL of milatuzumab, control mAbs, or medium
only for 3 days. The effect of each treatment on APC subsets was evaluated by costaining the cells with PE-labeled anti-CD14 and anti-CD19 IgG, in combination with
allophycocyanin-labeled antieBDCA-1 IgG, for analysis of mDC1, or a mixture of FITC-labeled antieBDCA-2 and allophycocyanin-labeled antieBDCA-3 IgG for
simultaneous analysis of mDC2s and pDCs, respectively. PBMCs were gated to exclude the debris and dead cells on the basis of their forward scatter and side scatter
characteristics. (A) Subpopulations of PBMCs were gated as follows: monocytes, CD14þSSCmedium; B cells, CD19þSSClow; T cells, CD19CD14SSClow; mDC1,
CD14CD19BDCA-1þ; mDC2, CD14CD19BDCA-3þþ; pDCs, CD14CD19BDCA-2þ. (B-E) Representative ﬂow cytometry data for B cells (B), monocytes (B), non-B
lymphocytes (B), mDC1s (C), mDC2s (D), and pDCs (E) in PBMCs after mAb treatment. (F-H) Mean percentages of live mDC1s, mDC2s, and pDCs in PBMCs after mAb
treatment (n ¼ 7 donors). Error bars indicate SD. P values were determined by the paired t test. **P<.05; ***P<.01 versus hMN-14 control.
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CD20) was purchased from IDEC Pharmaceuticals (San Diego, CA). Alemtu-
zumab (anti-CD52) was obtained from Genzyme (Ridgeﬁeld, NJ). The mAbs
used for ﬂow cytometry were obtained from BD Pharmingen (San Jose, CA):
FITC-labeled anti-CD74 (M-B741), FITC-labeled mouse IgG1, PE-labeled anti-
CD25, PerCp-labeled anti-CD8, and allophycocyanin-labeled anti-CD4 and
CD3; or from Miltenyi Biotec (Auburn, CA): PE-labeled mAbs to CD19 (LT19)
and CD14 (TÜK4) and allophycocyanin-labeled mAbs to BDCA-1 (AD5-8E7),
BDCA-2 (AC144), and BDCA-3 (AD5-14H12). Human IgG was obtained from
Jackson ImmunoResearch (West Grove, PA). HLA-A*0201 restricted CMV
pp65 peptide (NLVPMVATV) and HIV gag peptide (SL9, SLYNTVATL) were
obtained from Anaspec (Fremont, CA).Assessment of APC Subsets in PBMCs
Buffy coats from expired whole blood were obtained from healthy
donors at the Blood Center of New Jersey (East Orange, NJ), after approval by
the New England Institutional Review Board. PBMCs were isolated from
buffy coats by standard density-gradient centrifugation over Ficoll-Paque.
The isolated PBMCs were treated with milatuzumab or other mAbs at
37C in 5% CO2 for 3 days. After incubation, the cells were stained with PE-labeled anti-CD14 and anti-CD19 in combination with allophycocyanin-
labeled anti-BDCA-1. After washing, the cells were analyzed by ﬂow
cytometry using the gating strategy described below. Live PBMCs were
gated based on forward scatter and side scatter signals. Within live PBMCs,
type 1 mDCs (mDC1s) were identiﬁed as CD1419BDCA-1þ cell pop-
ulations [31], and the lymphocyte population was analyzed for B cells
(CD19þSSClow), non-B lymphocytes (primarily T cells) (CD1914SSClow),
and monocytes (CD14þSSCmedium). To measure the frequencies of pDCs and
type 2 mDCs (mDC2s), PBMCs were stained with PE-labeled anti-CD14 and
anti-CD19 IgG, in combination with FITC-labeled antieBDCA-2 and
allophycocyanin-labeled antieBDCA-3 IgG. Within the live PBMCs, mDC2s
were identiﬁed as the CD1419BDCA-3þ cell population, whereas pDCs
were identiﬁed as the CD1419BDCA-2þ cell population [31]. Flow
cytometry was performed using a FACSCalibur (BD Biosciences, San Jose,
CA), and data were analyzed with FlowJo software (Tree Star, Ashland, OR).Assessment of T-Cell Apoptosis and Survival
Human PBMCs were treated with hMN-14, milatuzumab, or alemtuzu-
mab at different concentrations for 18 hours in the presence of phytohe-
magglutinin (ﬁnal concentration, 2.5 mg/mL) and IL-2 (ﬁnal concentration,
Figure 1. (continued).
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488elabeled annexin V, PE-labeled anti-CD25, and allophycocyanin-labeled
anti-CD3. After washing, the cells were stained with 7-aminoactinomycin-D
(7-AAD; Life Technologies, Grand Island, NY), followed by ﬂow cytometry
analysis of early (annexin Vþ7-AAD) and late apoptotic cells (annexin Vþ7-
AADþ) and live cells (annexin V7-AAD) [31] in activated T cells
(CD3þCD25þ) and nonactivated T cells (CD3þCD25) within PBMCs.
Two-Way Allo-MLR
Proliferation of T cells in the presence of APCs was evaluated by 2-way
allo-MLR without irradiation of PBMCs from either donor [31,32]. PBMCs
from different donors were labeled with 1 mM carboxyﬂuorescein succini-
midyl ester (CFSE; Life Technologies) following the manufacturer’s instruc-
tions. After extensive washing, cells from different donors were mixed with
one another at a 1:1 ratio and then cultured with milatuzumab or control
mAbs at 37C in 5% CO2 for 7-10 days. Starting on day 4, human IL-2 (ﬁnal
concentration 50 U/mL; Roche Applied Science, Penzburg, Germany) was
added to the culture, and the cells were split every other day by adding fresh
medium without mAbs. To analyze cell proliferation, cells were harvested,
and the CFSElow cell frequencieswere quantitated byﬂowcytometry. In some
experiments, cells fromMLRswere stainedwith anti-CD4andanti-CD8mAbs
for ﬂow cytometry analysis of the percentages of T-cell subsets in allo-MLRs.
Hu-PBL-SCID Mouse Model of GVHD
All animal procedures were approved by the Institutional Animal Care
and Use Committee of the University of Medicine and Dentistry of New
Jersey. The hu-PBL-SCID mouse model of GVHD was established by
following the method of Wilson et al. [27]. SCID mice (C.B-Igh-1b/IcrTac-
Prkdcscid; 5-7 weeks old) were purchased from Taconic (Rensselaer, NY),
housed in sterile microisolation cages, and given autoclaved food and water.
After a 10-day acclimation period, on study day1, eachmousewas injected
i.p. with 20 mL of asialo-GM-1 (Wako Chemicals, Richmond, VA) and irra-
diated (325 cGy). On the next day (day 0), 5  107 fresh human PBMCs in
200 mL of serum-free therapeutic-grade AIM-V medium (Life Technologies)
were transplanted into each mouse by i.p. injection. Milatuzumab or control
Abs were administered by i.p. injection at 3 h before human PBMC trans-
plantation, with doses of 350 and 700 mg/mouse, equivalent to 1.46 and
2.92 mg/kg in humans. Mice were then assessed daily using a GVHD scoring
system that measures 6 items related to clinical signs of GVHD: weight loss,
posture, activity, fur texture, skin integrity, and diarrhea [27]. The overall
score for each mouse was the sum of the 6 individual scores (0-2 points for
each). Mice with severe GVHD (overall score 5) or at the end of study (day28) were euthanized, and livers, spleens, and lungs were obtained for
analysis. Before euthanasia, peripheral blood was collected for serum
cytokine measurements using a chromatic bead assay (CBA) kit (BD
Biosciences). Livers, spleens, and lungs were ﬁxed in 10% formalin,
embedded in parafﬁn, and sectioned for hematoxylin and eosin histological
examination of periportal lymphocytic inﬁltration, as well as immunohis-
tochemical staining for human CD3þ and CD74þ cells, using the humanized
mAbs IMMU-T3 and milatuzumab, respectively, as described previously
[33]. In addition, blood samples collected from cardiac puncture of anes-
thetized animals were used for measuring circulating Th1/Th2 cytokines by
CBA (BD Biosciences).
Quantitation of CMV-Speciﬁc T Cells in Allo-MLR by Assessing CMV-
Speciﬁc IFN-g Response
PBMCs from donors with HLA-A*0201erestricted, CMV-speciﬁc IFN-g
responses, as precharacterized by Cellular Technology (Shaker Heights, OH),
were mixed with PBMCs from other donors, irrespective of HLA type and
CMV status, in the presence of milatuzumab or control mAbs at 5 mg/mL. The
mixed cells were cultured for 4 days in RPMI-1640 medium with 10% fetal
bovine serum (FBS), followed by the addition of 50 U/mL of IL-2, and then
cultured for another 2 days. Cells were then harvested and incubated with
CMV pp65 peptide (NLVPMVATV) [27] or HIV gag peptide (SL9; SLYNTVATL)
[27] at 10 mg/mL for 6 hours in the presence of brefeldin A at a ﬁnal
concentration of 1 mg/mL. The cells were then stained with PerCp-CD3 and
FITC-CD8, followed by permeabilization and ﬁxation using BD Cytoﬁx/
Cytoperm solution (BD Pharmingen) and intracellular staining with allo-
phycocyanin-IFN-gmAb. The percentages of IFN-gþ cells stimulated by CMV
pp65 peptides in total MLR cells and CD3þCD8þ cells were determined by
ﬂow cytometry.
Statistical Analyses
Statistical signiﬁcance between mAb treatment and controls was
assessed using the paired t test. Animal survival data were analyzed with
Prism (GraphPad Software, La Jolla, CA). Body weight changeswere analyzed
by analysis of variance using a generalized linear model approach, and
GVHD clinical scores were analyzed using a generalized estimation equa-
tions approach [34] with SAS software (SAS Institute, Cary, NC).
RESULTS
Milatuzumab Selectively Reduces mDCs
To test the potential cytotoxicity of milatuzumab on DCs
and other hematopoietic APC subsets, human PBMCs were
Figure 2. Milatuzumab suppresses T-cell proliferation in allo-MLR. CFSE-labeled PBMCs from different donors were mixed with one another and incubated with 5 mg/
mL of milatuzumab or other mAbs (hMN-14, rituximab, or hLL1-Fab-A3B3), or medium only, for 8 days. IL-2 was added to the culture on day 4. On day 8, the cells
were harvested and analyzed by ﬂow cytometry. Proliferating cells were quantitated by measuring CFSElow cell frequencies. Representative data from one
combination of stimulator/responder PBMCs are shown in (A), and statistical analysis of all combinations is shown in (B). (C) In another experiment, allo-MLRs and
mAb treatments were the same as in (A) and (B), but stained with PerCp-labeled CD4 and allophycocyanin-labeled CD8, followed by ﬂow cytometry analysis of the
CFSElow cell frequencies in gated CD4þ and CD8þ T cells. (D) Statistical analysis of CD4þ and CD8þ T cells with diluted CFSE. CD4high T cells in total live cells of allo-
MLRs were gated and analyzed (n ¼ 10 stimulator/responder combinations from 5 donors). Error bars indicate SD. Statistical signiﬁcance was determined by the
paired t test.
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followed by the enumeration of various APC subsets in
PBMCs. As shown in Figure 1A-C, mDC1 cells (deﬁned as the
CD14CD19BDCA-1þ cell population [31]) in milatuzumab-
treated PBMCs were reduced by 59.8% compared with
control anti-carcinoembryonic antigen (CEACAM5; CD66e)
antibody hMN-14etreated cells (P ¼ .0158, n ¼ 4 donors)
(Figure 1C), and B cells were reduced by 21.1% (P ¼ .0035,
n ¼ 4 donors), whereas in monocytes (CD14þSSChigh cell
population) and noneB lymphocytes (CD14CD19 cell
population, >80% T cells [33]) were not affected (Figure 1B).
In separate experiments, mDC2 cells (CD14CD19BDCA-3þ
cell population [31]) were reduced by 53.8% (P < .05, n ¼ 7
donors) (Figure 1D), and pDCs (CD14CD19BDCA-2þ cell
population) were not affected (Figure 1E). As expected, rit-
uximab, the chimeric anti-CD20mAb, signiﬁcantly reduced B
cells (53.2% reduction; P ¼ .0129, n ¼ 4 donors) (Figure 1B)
but had no effect on monocytes, DCs, or non-B lymphocytes(Figure 1B and E). Similar results were obtained in human
whole blood, in which milatuzumab at 5 mg/mL decreased
mDC1 and B cells, but not T cells, after 2 days of incubation
in vitro (Supplemental Figure S1A). The differential effects of
milatuzumab on different PBMC subsets may be related to
the different expression levels of CD74 on these cells. As
shown in Supplemental Figure S2A and B, the CD74 expres-
sionwas highest onmDC2s andmDC1s and lowest on noneB
lymphocytes, which is correlated with the efﬁcacy of
reduction on APC subsets by milatuzumab (Supplemental
Figure S2C and D).
Compared with milatuzumab, the Fab fragment of mila-
tuzumab (hLL1-Fab-A3B3), which is linked to an irrelevant
A3B3 protein domain of CEACAM5 [30], did not exhibit any
effect on all APC subsets (Figure 1F-H), indicating that either
divalent binding or the Fc Ab portion is required for the
action of milatuzumab. However, milatuzumab failed to kill
puriﬁed mDC1s or mDC2s (Supplemental Figure S3A and B),
Figure 3. Milatuzumab has no effect on activated or nonactivated T cells. Human PBMCs were treated with milatuzumab, control mAb hMN-14, or alemtuzumab at
the indicated concentrations for 18 h in the presence of 2.5 mg/mL of phytohemagglutinin and 50 U/mL of IL-2. The cells were then stained with Alexa Fluor
488elabeled annexin V, PE-labeled anti-CD25, allophycocyanin-labeled anti-CD3, and 7-AAD for ﬂow cytometry analysis. (A) Gating proﬁle of early apoptotic cells,
late apoptotic cells, and live cells in activated T cells (CD3þCD25þ) and nonactivated T cells (CD3þCD25). (B and C) Apoptotic and live cells in activated T cells (B) and
nonactivated T cells (C) (n ¼ 6 PBMC donors). *P < .05; **P < .01; ***P < .001 versus hMN-14 control.
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Figure 4. Milatuzumab prevents acute GVHD in SCID mice undergoing transplantation with human PBMCs. After sublethal total body irradiation (3.25 Gy), 40 SCID
mice were grouped into 10 blocks following a randomized block design. The 4 mice in each block received 5  107 human PBMCs i.p. from the same donor. At 3 hours
before transplantation, each of the 4 mice in each block was either untreated or given an i.p. injection of milatuzumab (350 or 700 mg) or alemtuzumab (5 mg).
Throughout the 28-day study period, GVHD scores and body weight were assessed daily. Mice were euthanized at a GVHD score of 5. (A) Euthanized or spon-
taneously expired mice were recorded for survival analysis by each treatment. (B) Daily recordings of total GVHD scores and survival over the full 28-day study period.
(C) Summary of total GVHD scores. (D) Body weight loss. Signiﬁcant prevention of mortality (A) and body weight loss (D) was seen in the milatuzumab- and
alemtuzumab-treated mice. Milatuzumab also reduced GVHD scores in a dose-dependent manner (B and C). The survival data (A) were analyzed using GraphPad
Prism. GVHD clinical scores (B and C) were analyzed using the generalized estimation equation approach, and body weight changes (D) were analyzed by analysis of
variance.
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human PBMCs may occuring through the ligation of other
cell types by the Fc of milatuzumab.Milatuzumab Inhibits Allo-MLR
Because DCs are the most potent APCs for stimulating
Tcells, we next investigatedwhether the reduction of mDC1s
Figure 4. (continued).
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reduced T-cell proliferation in 2-way allo-MLRs [31,32]. After
8 days of culture, allo-MLRs treated with the control anti-
CEACAM5 mAb hMN-14 exhibited T-cell proliferation, char-
acterized by 23.7% of cells with CFSE dilution. In contrast,
T-cell proliferation was detected in only 8.4% of cells in
allo-MLRs treated with milatuzumab (Figure 2A). Statistical
analysis of 10 different stimulatoreresponder combinations
showed a signiﬁcant reduction (P < .0001) in T-cell prolif-
eration in milatuzumab-treated allo-MLRs (Figure 2B).
Milatuzumab also inhibited proliferation of both CD4þ and
CD8þ T cell subsets in allo-MLRs (Figure 2C and D). The
proliferation of CD4high T cells, a subpopulation of activated
CD4þ T cells [35], was inhibited as well (Figure 2D). No
inhibition was found in hLL1-Fab-A3B3etreated allo-MLRs,
suggesting that the inhibition of T-cell proliferation of allo-
MLRs by milatuzumab also requires the Fc portion or diva-
lent binding.
To exclude the possibility that milatuzumab might have
direct cytotoxicity on activated T cells, we tested the effect of
milatuzumab on apoptosis and survival of activated (CD25þ)
and nonactivated (CD25) T cells in phytohemagglutinin-
stimulated PBMCs. The results showed that milatuzumab
has no effect on early and late apoptosis or survival in either
activated or nonactivated T cells (Figure 3A-C), which is
consistent with the lack of CD74 expression in total T cells
(Supplemental Figure S2). In comparison, the anti-CD52mAb
alemtuzumab induced early apoptosis and reduced survival
of T cells (Figure 3A-C). Thus, the inhibitory effect of mila-
tuzumab on allo-MLRs is likely due not to a direct cytotoxic
effect on T cells, but rather to the reduction of mDCs and B
cells, or to the antagonistic blocking of MIF by milatuzumab.
As the ligand of CD74, MIF plays an essential regulatory role
in T-cell activation [36].
Milatuzumab Prevents Acute GVHD in hu-PBL-SCID Mice
The reduction ofmDCs and inhibitionof allo-MLRs suggest
that milatuzumab may be therapeutic for GVHD. We testedthis possibility in a xenogeneic SCID mouse model in which
acute GVHD is mediated by engrafted human donor CD4þ T
cells andDCs [27]. As shown in Figure 4A, 90% (9 of 10) ofmice
injected i.p. with either 350 or 700 mg of milatuzumab at 3 h
before transplantation survived for the full 28-day experi-
mental period, comparedwith only 20% (2 of 10) of untreated
mice (P < .0012). All of the 8 untreated mice that did not
survive died spontaneously (ie, were found dead at the daily
checkup) on day 10-15 (Figure 4B). In the mice treated with
milatuzumab 350 mg and 700 mg, only 1 of the 10mice in each
group did not survive the full study period (28 days). Both of
these mice died spontaneously, one on day 20 (the 350 mg
milatuzumab-treated mouse) and the other on day 13 (the
700 mg milatuzumab-treated mouse) (Figure 4B). Before they
were founddead, the animals exhibitedhunching, fur rufﬂing,
reduced activity, and greater weight loss, but no diarrhea or
skin lesions. In the sameexperiment, 5mgof the clinicallyused
anti-GVHD anti-CD52mAb alemtuzumab protected 100% (10
of 10) of the mice at day 28.
We also performed direct temporal comparisons of GVHD
clinical scores and weight loss between treatments over the
full 28-day experiment. Throughout the study, GVHD scores,
body weight changes, and survival were assessed on a daily
basis. Mice were euthanized at a GVHD score of5. Figure 4B
shows daily-recorded GVHD scores in each hu-PBL-
SCID mouse over the full 28-day study period, which
demonstrate that both milatuzumab and alemtuzumab
reduced GVHD scores in this xenogeneic animal model, and
in 9 of 10 blocks of mice (Figure 4B, a-d and f-j), milatuzumab
reduced the scores in a dose-dependent manner. Whereas
untreated control hu-SCID mice experienced severe GVHD,
mice treated with either milatuzumab (350 or 700 mg) or
alemtuzumab (5 mg) had signiﬁcantly lower GVHD scores
(Figure 4B and C; P < .001) and less body weight loss
(Figure 4D; P< .001). Similar results also were obtained from
an earlier pilot animal study, showing that 2 of 2
milatuzumab-treated hu-SCID mice had much lower GVHD
scores, less or no bodyweight loss, and no deaths throughout
Figure 5. Milatuzumab eliminates human T-cell and APC inﬁltration in GVHD
target organs. At the end of the experiment shown in Figure 3, all surviving
mice were euthanized. GVHD target organs (lungs, livers, and spleens) were
collected for pathological analysis. Human T cells and APCs within the GVHD
target organs were identiﬁed by immunohistochemical labeling of human CD3
and CD74, respectively. Representative specimens are shown, with indications
of human CD3þ T cells and CD74þ APCs in the specimens from untreated mice
(A), but not in those from milatuzumab-treated mice (B). Perivascular
lymphocytic engraftment is also evident in the hematoxylin and eosine-
stained sections (arrows in A).
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body weight loss, and spontaneous death or mandatory
euthanasia in both untreated mice (Supplemental Figure S4A
and B). In another animal study, all (5 of 5) hu-PBL-SCIDmice
treated with milatuzuamb 350 mg or 700 mg or alemtuzumab
5 mg survived to day 11 when the study was terminated,
whereas only 2 of 5 untreated or control antibody
hMN-14etreated (700 mg) hu-PBL-SCID mice survived at this
time point.Milatuzumab Eliminates Inﬁltration of CD3þ and CD74þ
Donor Cells in GVHD Target Organs
At the end (day 28) of the study shown in Figure 3, all
surviving mice were euthanized to collect GVHD target
organs (ie, lungs, liver, and spleen) and peripheral blood for
histopathological and cytokine analyses, respectively.
Immunohistochemistry showed human CD3þ T cells inﬁl-
trating the lungs, liver, and spleen in untreated mice
(Figure 5A), but not in milatuzumab-treated mice (Figure 5B)
or alemtuzumab-treated mice (data not shown). These
results provide histopathological evidence that acute GVHD
was present in the untreated mice, and that milatuzumaband alemtuzumab effectively controlled acute GVHD in this
xenogeneic model.
Like human CD3þ cells, human CD74þ cells were detected
in the lungs, liver, and spleen of untreated mice (Figure 5A),
but not in milatuzumab-treated mice (Figure 5B) or
alemtuzumab-treated mice (data not shown). Because CD74
is expressed in both APCs and a subset of activated T cells [7],
the human CD74þ cells represent donor APCs, including
mDCs, and a subset of activated T cells in this xenogenic
model. The disappearance of these cells in GVHD target
organs in milatuzumab-treated mice provides evidence that
milatuzumab controls GVHD by a CD74-dependent mecha-
nism. It remains to be determined whether milatuzumab,
in an in vivo environment, can directly kill donor-derived
APCs and activated T cells in the GVHD target organs of this
model, or can simply inhibit the recruitment of these cells to
these organs through the antagonistic blocking of MIF on
CD74.
Milatuzumab Suppresses Human Cytokine Storm in hu-
PBL-SCID Mice
In addition to clinical signs and pathological changes,
acute GVHD is also characterized by a human “cytokine
storm,” characterized by elevated serum levels of IFN-g, TNF-
a, IL-1, IL-5, IL-6, and IL-8 [27,37]. These inﬂammatory cyto-
kines are responsible for or contribute to the tissue damage
and clinical manifestations of acute GVHD. The anti-CD52
mAb alemtuzumab and anti-CD83 polyclonal antibody that
targets mature DCs reportedly can suppress this cytokine
storm in parallel to their efﬁcacy against GVHD in hu-PBL-
SCID mice [27]; thus, we examined whether milatuzumab
affected serum levels of proinﬂammatory cytokines at the
end of the animal study (ie, day 28 posttransplantation). The
results demonstrate that milatuzumab at 350 or 700 mg
substantially reduces the serum levels of IFN-g (by 4w5-fold;
P < .001) and IL-5 (by 5w7-fold; P < .001), but has no
signiﬁcant effect on TNF-a, IL-2, IL-4, and IL-10 (Figure 6A
and B). Similar results were obtained by treatment with
alemtuzumab. Thus, milatuzumab is capable of suppressing
the cytokine storm in acute GVHD.
Milatuzumab Does Not Affect CMV-Speciﬁc T-Cell
Immunity
We showed thatmilatuzumab reducesmDC1s andmDC2s
but spares CD74 non-B lymphocytes (Figure 1B), which are
composedmainly of Tcells [31], and has no effect on activated
or nonactivated T cells (Figure 1C). These results led us to
postulate that milatuzumab may preserve preexisting
pathogen-speciﬁc memory T cells, which are essential for
immunologic control of posttransplantation opportunistic
infections. To verify this, we examined milatuzumab’s effects
on the survival and function of CMV-speciﬁc T cells in 2-way
allo-MLRs in which hPBMCs from CMVþ, HLA-A*0201
donors (n ¼ 5) were mixed with allogeneic PBMCs from
other donors (n¼ 5)with uncharacterized HLA type and CMV
status. The results, shown in Figure 7A and Supplemental
Figure S5A and B, demonstrate that on stimulation with
CMV pp65 peptide (NLVPMVATV), the frequencies of IFN-
geproducing cells in total MLR cells were no different in
milatuzumab-treated (0.474  0.327%), control hMN-
14etreated (0.486  0.336%), and rituximab-treated
(0.452  0.355%) MLRs. In contrast, alemtuzumab-treated
MLRs had much lower frequencies of IFN-geproducing cells
than the control antibody hMN-14etreated MLRs
(0.076  0.032% versus 0.486  0.336%; P ¼ .044, n ¼ 5).
Figure 6. Milatuzumab suppresses the human cytokine storm in hu-PBL-SCID mice. At the end of the same experiment shown in Figures 3 and 4, mouse serum
samples obtained at the end of the study (day 28) were analyzed for human Th1/Th2 cytokines by CBA. Data in (A) were obtained from 1 of the 2 blocks of mice given
human PBMCs from 2 different donors. Only 2 of the 10 untreated mice survived to the end of the study (day 28), compared with 9 of the 10 milatuzumab-treated
mice and all 10 of the alemtuzumab-treated mice. Therefore, only 2 blocks of mice, including the 2 surviving untreated mice together with their corresponding
treated mice, were available for paired analyses. The statistical analysis of serum cytokine levels in all surviving mice is shown in (B) (n ¼ 2 untreated surviving mice
versus n ¼ 9-10 milatuzumab- or alemtuzumab-treated surviving mice). Error bars indicate SD. Statistical signiﬁcance was determined with the t test. ***P < .001
versus untreated.
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gated CD3þCD8þ cells inmilatuzumab-treated (1.831.09%),
hMN-14etreated (1.91  1.12%), and rituximab-treated
(1.54  0.95%) MLRs (Figure 7B and Supplemental
Figure S5C and D). Alemtuzumab-treated MLRs had lower
frequenciesof IFN-geproducing cells ingatedCD3þCD8þ cells
compared with the control antibody hMN-14etreated MLRs
(0.810.83%versus 1.911.12%; n¼5), but thedifferencedid
not reach statistical signiﬁcance (P ¼ .1169), because alemtu-
zumab depleted both IFN-geproducing cells and the
CD3þCD8þ cells, lessening its effect on the frequencies of IFN-
geproducing cells in CD3þCD8þ cells. These results suggest
that milatuzumab maintains protective antiviral memory T-
cell immunity, thus differing from the clinically used T-
celledepletingmAbalemtuzumab,which causes high rates of
CMV infection and reactivation [3-6].
DISCUSSION
In this study, we have shown that milatuzumab,
a humanized anti-CD74 antagonistic mAb, can reduce
myeloid DCs and B cells, suppress the proliferation of allo-
MLRs, and effectively prevent acute GVHD in a humanized
SCID mouse model (hu-PBL-SCID). In this human/mouse
xenogeneic GVHD animal model, a single i.p. administration
ofmilatuzumabbefore humanPBMC transplantation lowered
GVHD clinical scores, prevented weight loss, eliminated
human lymphocyte inﬁltration in GVHD target organs, sup-
pressed the cytokine storm, and signiﬁcantly improved the
survival of hu-PBL-SCID mice (90% versus 20% untreated
controls).This is the ﬁrst report showing that GVHD can be
controlled by an antagonist mAb against CD74. Importantly,
this antibody does not affect the survival of T cells, including
activated T cells, or antiviral T-cell immunity, as evidenced by
the preserved CMV-speciﬁc CD8þ T cells in treated allo-
MLRs, suggesting that milatuzumab may not compromise
protective T-cell immunity against opportunistic infections.
Because the graft-versus-leukemia (GVL) effect, the principal
beneﬁt and major therapeutic goal of allo-HSCT, is also
mediated by donor T cells, the lack of effect of milatuzumab
on the survival of T cells implies that milatuzumab alsomight
not affect GVL. These promising results support further
preclinical studies to examine this novel antibody for
prophylactic and/or therapeutic control of GVHD.
Acute GVHD developed in hu-PBL-SCID mice is mediated
by the engrafted human T cells and DCs [27]. In this animal
model, the host (murine) APCs play aminor role inmediating
GVHD [27]. In GVHD patients, donor APCs contribute to the
development of GVHD through the pathway of “indirect
presentation” by processing and presenting host antigens to
donor Tcells [21-23], amongwhichmDCs are a critical subset
for presenting alloantigens after experimental bone marrow
transplantation [24]. Thus, the effective control of GVHD in
hu-PBL-SCIDmice bymilatuzumabmay be related, at least in
part, to its ability to selectively reduce donor mDCs, thereby
affecting the indirect presentation for GVHD development
[17]. This is similar to RA83, a polyclonal anti-CD83 antibody
that effectively controls acute GVHD in hu-PBL-SCID mice
through a proposed mechanism in which RA83 selectively
depletes activated donor human DCs that express CD83
Figure 7. CMV-speciﬁc CD8þ T cells are preserved in allo-MLRs after exposure to milatuzumab. PBMCs from CMVþ HLA-A*0201 donors (n ¼ 5) were mixed with
allogeneic PBMCs from other donors (n ¼ 5) with uncharacterized HLA type and CMV status. The mixed cells were cultured in the presence of milatuzumab or other
mAbs for 8 days, followed by stimulation with CMV pp65 peptide (NLVPMVATV) or HIV gag peptide at 10 mg/mL for 6 hours. The cells were ﬁrst stained with PerCp-
labeled anti-CD3 and FITC-labeled anti-CD8, and then, after permeabilization and ﬁxation, were intracellularly stained with allophycocyanin-labeled anti-IFN-g. (A)
Frequencies of CD3þIFN-gþ cells in total MLR cells. (B) IFN-gþ cells in gated CD3þCD8þ cells. Data shown are representative of 5 donorerecipient pairs of MLRs from 1
of 3 independent experiments.
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however, and thus RA83 could deplete activated donor Tcells
as well, which might be an additional mechanism contrib-
uting to its therapeutic efﬁcacy against GVHD.
In typical allo-HSCT, recipient hematopoietic and non-
hematopoietic APCs play critical roles in the development of
GVHD [15-21,23] via “direct presentation” [17,21]. Because of
the lack of animal models, we have not evaluated the effect
of milatuzumab on recipient hematopoietic and non-
hematopoietic APCs. The hu-PBL-SCID mouse model only
allows us to evaluate the effect of milatuzumab on donor
APCs. However, because milatuzumab is cross-reactive with
monkey CD74 [39], we would expect monkey GVHD models,
if available, to be useful for testing the effect of milatuzumab
on recipient APCs in vivo. Therapeutic evaluation of milatu-
zumab in monkey GVHD models may provide more relevant
information for the future clinical use of this mAb in GVHD
prevention.
Along with the reduction of mDCs, other possible mech-
anismsmay be implicated in the therapeutic control of GVHD
by milatuzumab. One of these mechanisms may be through
MIF, the natural ligand of CD74 and a pleiotropic proin-
ﬂammatory protein participating in many inﬂammatory
diseases [40]. Patients with acute GVHD reportedly have
higher serum MIF levels [41] and up-regulated local expres-
sion [42], and inamurinemodel of allogeneic SCT, knockoutoftheMIF gene in donor cells signiﬁcantly prevents the onset of
acute GVHD [28], suggesting that MIF/CD74 is actively
involved in GVHD. MIF induces inﬂammation through the
binding of CD74 [43]. It also binds CXCR2, CXCR4, and CD74,
forming a complex to trigger chemotaxis of monocytes and T
cells [44], which may promote the recruitment of leukocytes
into GVHD target organs to cause tissue damage. Moreover,
MIF increases leukocyteeendothelial interactions through
up-regulation of adhesion molecules on epithelial cells [45],
possibly via CD74. In addition, after engagement of
CD74, MIF stimulates the production of IL-8 [46], a proin-
ﬂammatory cytokine involved in various human inﬂamma-
tory diseases [47] and a biomarker for GVHD [48]. MIF is
a chemoattractant that attracts neutrophils to local sites of
inﬂammation [47], possibly contributing to the inﬁltration
of donor leukocytes to GVHD target organs. MIF also stimu-
lates TNF-a production, which precedes and involves
the pathogenesis of acute GVHD [49]. As a CD74 antagonist
antibody, milatuzumab may target these pathways to
inhibit local inﬂammation and prevent the recruitment
of leukocytes, including T cells and APCs, into GVHD local
sites.
Given MIF/CD74’s essential role in T-cell activation [36], it
is also expected that milatuzumab, although having no effect
on T-cell survival, may modulate the activation status of T
cells via antagonistic blocking of MIF/CD74. Because
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modulation of the activation status of donor human T cells
may be another mechanism contributing to the anti-GVHD
efﬁcacy of milatuzumab in hu-PBL-SCID mice.
Furthermore, milatuzumab down-regulates the expres-
sion of adhesion molecules in human B cells, including L-
selectin (CD62L) and b7-integrin [13]. It remains to be shown
whethermilatuzumab has a similar effect on thesemolecules
in T cells, given that a4b7-integrin plays a central role in the
homing of T cells to the gut, a major GVHD target organ, and
that the absence of b7-integrin decreases the homing of
activated T cells to the intestine, resulting in less GVHD [50].
In addition, it has been reported that L-selectin and b7-
integrin on donor CD4þ T cells are required for the early
migration of these cells to gut-associated organized lymphoid
tissues, such as mesenteric lymph nodes and Peyer patches.
Inactivation of the genes encoding these two molecules
markedly reduces the accumulation of donor T cells in gut-
associated organized lymphoid tissues and the severity of
GVHD [51]. Thus, it would be of interest to investigate
whether milatuzumab down-regulates these molecules on T
cells as well.
In summary, this is the ﬁrst report showing that GVHD
can be controlled by an antagonist mAb targeting CD74
without impairing the protective T-cell immunity essential
for antiviral and GVL effects after allo-HSCT. Our results
support further investigation of CD74 as a novel therapeutic
target for GVHD and of the prophylactic and/or therapeutic
use of the anti-CD74mAbmilatuzumab for the control of this
challenging disease.
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